Paper28596207
Delayed progression of bull's eye maculopathy.
Jain S and 1 other. BMJ Case Rep, 2017. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Delayed progression of bull's eye maculopathy. Papers, record 28596207. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28596207
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antirheumatic Agents | Major topic |
| Chloroquine | Major topic |
| Macular Degeneration | Major topic |
| Retinal Diseases | Major topic |
| Aftercare | |
| Aged | |
| Disease Progression | |
| Electroretinography | |
| Female | |
| Fluorescein Angiography | |
| Humans | |
| Outcome Assessment, Health Care | |
| Tomography, Optical Coherence | |
| Vision Disorders | |
| Visual Acuity |
Source PubMed
References7
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17264974 | Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration? | Clin Rheumatol | 2007 | https://conductscience.org/library/papers/17264974 | PubMed |
| 2 | 23580861 | Delayed onset chloroquine retinopathy presenting 10 years after long-term usage of chloroquine. | Middle East Afr J Ophthalmol | 2013 | https://conductscience.org/library/papers/23580861 | PubMed |
| 3 | 24187053 | Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation. | Br J Ophthalmol | 2014 | https://conductscience.org/library/papers/24187053 | PubMed |
| 4 | 24922444 | Effect of disease stage on progression of hydroxychloroquine retinopathy. | JAMA Ophthalmol | 2014 | https://conductscience.org/library/papers/24922444 | PubMed |
| 5 | 25275721 | The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. | JAMA Ophthalmol | 2014 | https://conductscience.org/library/papers/25275721 | PubMed |
| 6 | 26992838 | Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). | Ophthalmology | 2016 | https://conductscience.org/library/papers/26992838 | PubMed |
| 7 | 3964626 | Delayed-onset chloroquine retinopathy. | Br J Ophthalmol | 1986 | https://conductscience.org/library/papers/3964626 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37767541 | Ophthalmologic implications to consider when using hydroxychloroquine to treat COVID-19 and induced arthritis. | World J Exp Med | 2023 | https://conductscience.org/library/papers/37767541 | PubMed |
| 37418250 | Quantitative Fundus Autofluorescence in Systemic Chloroquine/Hydroxychloroquine Therapy: One Year Follow-Up. | Transl Vis Sci Technol | 2023 | https://conductscience.org/library/papers/37418250 | PubMed |
| 36412828 | Knowledge of Saudi Patients with Autoimmune Diseases about Hydroxychloroquine Toxicity: The Role of Physician-Patient Communication. | Pharmacy (Basel) | 2022 | https://conductscience.org/library/papers/36412828 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28596207
GET https://conductscience.org/api/papers/v1/28596207/authors